Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Baird Small/Mid Cap Growth Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively upgrading portfolio quality through selective healthcare and consumer additions."
In Q2 2025, the Baird Small/Mid Cap Growth strategy returned +4.46% (net of fees), underperforming its primary benchmark, the Russell 2500 Growth Index, which returned +11.31%. This relative underperformance was driven by a speculative, beta-led market rally focused on unprofitable, low-margin companies with AI-exposure, whereas Baird's high-quality and defensive tech, industrial, and healthcare holdings lagged. Key actions during the quarter included exiting several stagnant or decelerating positions (such as Globant, Trex, Wilscot, and PROCEPT BioRobotics) and deploying capital into promising new additions with distinct catalysts (such as Insmed, ADMA Biologics, Waystar, CAVA, e.l.f. Beauty, and MarketAxess). The manager expects continued macro and political volatility, which they plan to leverage for long-term portfolio positioning.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Growth Outlook
Market outlook remains moderate conviction: Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Risk Appetite
Risk appetite posture is moderate conviction: Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Forward Guidance
Forward guidance signal: Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Language Signal
Tone analysis indicates above average conviction language: Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Perceived Risk
Perceived risk level is evaluated as above average conviction. Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
Time Horizon
Investment time horizon reflects a high conviction orientation. Baird Small/Mid Cap Growth lagged a speculative, beta-driven benchmark rally in Q2 2025 (+4.46% net vs. +11.31%), but continues to focus on high-quality compounders while actively ...
